Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALXN2040 · 1 trial · 1 indication
To determine the effect of multiple doses of ALXN2040 on the single-dose PK of rosuvastatin.
To determine the effect of multiple doses of ALXN2040 on the single-dose PK of rosuvastatin.
To determine the effect of multiple doses of ALXN2040 on the single-dose PK of rosuvastatin.
To determine the effect of multiple doses of ALXN2040 on the single-dose PK of rosuvastatin.
To determine the effect of multiple doses of ALXN2040 on the single-dose PK of rosuvastatin.
To determine the effect of multiple doses of ALXN2040 on the single-dose PK of rosuvastatin.
To determine the effect of multiple doses of ALXN2040 on the single-dose PK of rosuvastatin.
To determine the effect of multiple doses of ALXN2040 on the single-dose PK of rosuvastatin.
To determine the effect of multiple doses of ALXN2040 on the single-dose PK of rosuvastatin.
To determine the effect of multiple doses of ALXN2040 on the single-dose PK of rosuvastatin.
To determine the effect of multiple doses of ALXN2040 on the single-dose PK of rosuvastatin.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Participants will receive a single dose of rosuvastatin in the morning of Day 1 in Treatment Period 1. Following a washout period of 5 days, participants will receive ALXN2040 three times daily on Days 1 through 7 in treatment period 2. |
| Name | Type | Description |
|---|---|---|
| Rosuvastatin | DRUG | In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040). |
| ALXN2040 | DRUG | In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7. |
Inclusion Criteria: * Medically healthy participants with no clinically significant or relevant abnormalities as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory safety evaluation (hematology, biochemistry, coagulation, and u...
ALXN2040 is an investigational small molecule being studied in healthy participants. It is not approved for any disease and is currently in Phase 1 clinical development. The only completed trial evaluated a potential drug interaction between ALXN2040 and rosuvastatin in healthy volunteers.
ALXN2040 is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical research on this investigational small molecule, with one completed Phase 1 trial in healthy participants.
ALXN2040 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently listed.
ALXN2040 has one completed clinical trial, NCT05708573, titled 'Potential Drug Interaction Between ALXN2040 and Rosuvastatin'. This Phase 1 study enrolled 20 healthy participants in the United States and was not randomized or blinded.
No alternative names for ALXN2040 have been disclosed. It is identified solely by the code name ALXN2040 in clinical trial records, and no other names are associated with this investigational small molecule.